HRP20120639T1 - Fumaratna sol (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola - Google Patents

Fumaratna sol (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola Download PDF

Info

Publication number
HRP20120639T1
HRP20120639T1 HRP20120639TT HRP20120639T HRP20120639T1 HR P20120639 T1 HRP20120639 T1 HR P20120639T1 HR P20120639T T HRP20120639T T HR P20120639TT HR P20120639 T HRP20120639 T HR P20120639T HR P20120639 T1 HRP20120639 T1 HR P20120639T1
Authority
HR
Croatia
Prior art keywords
compound
beta
mixture obtained
wetting agent
alpha
Prior art date
Application number
HRP20120639TT
Other languages
English (en)
Croatian (hr)
Inventor
Fran�ois Alexandre Lucas Hegyi Jean
Albert Alex Aelterman Wim
Lydia Lang Yolande
Carl Sigrid
Leys Carina
Jozef Maria Van Remoortere Peter
Faure Anne
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120639(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP20120639T1 publication Critical patent/HRP20120639T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20120639TT 2006-12-05 2007-12-03 Fumaratna sol (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola HRP20120639T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number Publication Date
HRP20120639T1 true HRP20120639T1 (hr) 2012-08-31

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120639TT HRP20120639T1 (hr) 2006-12-05 2007-12-03 Fumaratna sol (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola

Country Status (34)

Country Link
US (1) US8546428B2 (enExample)
EP (1) EP2086940B1 (enExample)
JP (2) JP2010511663A (enExample)
KR (1) KR101514700B1 (enExample)
CN (2) CN101547904A (enExample)
AP (1) AP2498A (enExample)
AR (1) AR064149A1 (enExample)
AU (1) AU2007328945B2 (enExample)
BR (1) BRPI0719693A2 (enExample)
CA (1) CA2668512C (enExample)
CL (1) CL2007003472A1 (enExample)
CY (1) CY1113594T1 (enExample)
DK (1) DK2086940T3 (enExample)
EA (1) EA017091B9 (enExample)
ES (1) ES2387923T3 (enExample)
HK (1) HK1214513A1 (enExample)
HR (1) HRP20120639T1 (enExample)
IL (1) IL199077A (enExample)
JO (1) JO2973B1 (enExample)
ME (1) ME01456B (enExample)
MX (1) MX2009005909A (enExample)
MY (1) MY148844A (enExample)
NO (1) NO342773B1 (enExample)
NZ (1) NZ576485A (enExample)
PE (1) PE20081350A1 (enExample)
PL (1) PL2086940T3 (enExample)
PT (1) PT2086940E (enExample)
RS (1) RS52408B (enExample)
SI (1) SI2086940T1 (enExample)
TW (1) TWI417098B (enExample)
UA (1) UA97813C2 (enExample)
UY (1) UY30762A1 (enExample)
WO (1) WO2008068231A1 (enExample)
ZA (1) ZA200903907B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) * 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
HUE062481T2 (hu) 2015-01-27 2023-11-28 Janssen Pharmaceutica Nv Diszpergálódó készítmények
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) * 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
EP3366676B1 (en) * 2015-10-20 2021-05-26 Zhejiang Hisun Pharmaceutical Co., Ltd Crystalline forms of bedaquiline fumarate and preparation methods therefor
AU2017298187B2 (en) * 2016-07-20 2019-11-14 Novartis Ag Aminopyridine derivatives and their use as selective ALK-2 inhibitors
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
JP7102500B2 (ja) 2017-07-14 2022-07-19 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
JP7654544B2 (ja) * 2018-12-13 2025-04-01 マンカインド コーポレイション ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法
JP2022516671A (ja) 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
CN116406270A (zh) 2020-11-12 2023-07-07 詹森药业有限公司 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
WO1998018326A1 (en) 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
IL122025A (en) * 1996-10-30 2003-01-12 Lilly Co Eli Use of raloxifene or pharmaceutically acceptable salts or solvates thereof, in the preparation of a medicament for preventing breast cancer
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
CN101070304B (zh) * 2002-07-25 2011-10-26 詹森药业有限公司 喹啉衍生物及其作为分枝杆菌抑制剂的应用
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
DE602005005810T2 (de) * 2004-05-28 2009-04-09 Janssen Pharmaceutica N.V. Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
KR101276571B1 (ko) * 2004-09-02 2013-06-18 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 푸마레이트
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법

Also Published As

Publication number Publication date
CY1113594T1 (el) 2016-06-22
UA97813C2 (uk) 2012-03-26
ES2387923T3 (es) 2012-10-04
CN101547904A (zh) 2009-09-30
AU2007328945B2 (en) 2014-04-03
EA017091B1 (ru) 2012-09-28
KR101514700B1 (ko) 2015-04-24
US20100028428A1 (en) 2010-02-04
BRPI0719693A2 (pt) 2013-12-24
MX2009005909A (es) 2009-06-16
CL2007003472A1 (es) 2008-08-22
AP2009004870A0 (en) 2009-06-30
NZ576485A (en) 2012-01-12
PL2086940T3 (pl) 2012-10-31
KR20090087020A (ko) 2009-08-14
IL199077A (en) 2016-09-29
WO2008068231A1 (en) 2008-06-12
TW200838527A (en) 2008-10-01
CA2668512C (en) 2015-03-24
CA2668512A1 (en) 2008-06-12
PT2086940E (pt) 2012-08-09
HK1214513A1 (zh) 2016-07-29
RS52408B (sr) 2013-02-28
JP2015028049A (ja) 2015-02-12
AR064149A1 (es) 2009-03-18
ZA200903907B (en) 2013-08-28
US8546428B2 (en) 2013-10-01
EA200970532A1 (ru) 2009-10-30
DK2086940T3 (da) 2012-08-20
MY148844A (en) 2013-06-14
NO20092535L (no) 2009-08-06
EA017091B9 (ru) 2014-10-30
JP2010511663A (ja) 2010-04-15
EP2086940A1 (en) 2009-08-12
JO2973B1 (en) 2016-03-15
TWI417098B (zh) 2013-12-01
UY30762A1 (es) 2008-07-03
AU2007328945A1 (en) 2008-06-12
NO342773B1 (no) 2018-08-06
EP2086940B1 (en) 2012-05-16
CN105012303A (zh) 2015-11-04
JP5894239B2 (ja) 2016-03-23
SI2086940T1 (sl) 2012-09-28
PE20081350A1 (es) 2008-09-18
ME01456B (me) 2014-04-20
AP2498A (en) 2012-10-19

Similar Documents

Publication Publication Date Title
HRP20120639T1 (hr) Fumaratna sol (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
JP2010511663A5 (enExample)
KR101573889B1 (ko) 속효성과 지속성을 동시에 갖는 약제학적 조성물
JP2009545560A5 (enExample)
TW200413006A (en) Solid dispersions comprising a hygroscopic and/or deliquescent drug
SI2659881T1 (en) Formulation of the delayed release medicinal product
CN102895208A (zh) 包衣片制剂和方法
HU202102B (en) Process for producing oral pharmaceutical compositions with controlled release of the active components
JP2008520736A5 (enExample)
EP2018157A2 (en) Controlled release formulation comprising anti-epileptic drugs
JP5881700B2 (ja) ブロナンセリン経口放出制御型医薬組成物
WO2013058450A1 (ko) 안정화된 에페리손 의약 조성물 및 이를 함유하는 서방성 제제
JP2020536953A5 (enExample)
US20090269402A1 (en) Modified release composition of at least one form of venlafaxine
US20130323309A1 (en) Sustained Release Composition of Memantine
JP6461142B2 (ja) イソニアジドの顆粒およびリファペンチンの顆粒を含むコーティング錠の形態の抗結核性の安定な医薬組成物ならびにその製造方法
AU2017252407A1 (en) Oral pharmaceutical compositions of nicotinamide
US10258577B2 (en) Multilayer solid pharmaceutical dosage forms
KR20140045925A (ko) 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
US20150366850A1 (en) Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
JP2009542669A (ja) ピペリジノアルカノールと充血除去剤の組み合わせを含んで成る医薬組成物
CN104274387A (zh) 美托洛尔缓释组合物
US11147767B2 (en) Gastroretentive formulations
WO2011016057A2 (en) Controlled release pharmaceutical compositions of milnacipran
SK2592001A3 (en) Pharmaceutical composition containing calcium valproate with delayed active substance release and method for the production of said composition